1. Medtech Insight

Nevro’s HFX Offers Durable Benefit In People Suffering Diabetic Pain

 
• By Reed Miller

New 24-month data from the SENZA-PDN trial, presented at the American Diabetes Society conference in New Orleans, provides more support for HFX 10 kHz as a reliable therapy for people with painful diabetic neuropathy.

Nevro's Senza Omnia HFX Spinal Cord Stimulation System
Nevro's Senza Omnia Implantable Spinal Cord Stimulator • Source: Nevro

Nevro is continuing to promote convincing clinical data to give it an edge in the increasingly competitive spinal cord stimulation (SCS) market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D